PROSCA/BLADDR 2020 | Second-line treatment of mHSPC

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, explores the difficulties of sequencing second-line therapies for metastatic hormone-sensitive prostate cancer (mHSPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).